A paradigm shift for the treatment of hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer: a review of CDK inhibitors

Mariane Teodoro Fernandes, Pedro Nazareth Aguiar, Carmélia Maria Noia Barreto et al.|Drugs in Context|2018

Cited by 11